Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

Arrowhead Pharmaceuticals  / Equity Bottom-Up

<ul><li>On May 9, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the second quarter of fiscal year 2024 that ended March 31, 2024.</li><li>The company currently has 14 clinical stage programs, with 10 of them being wholly owned.</li><li>We expect a total of 18 clinical programs by the year end.</li></ul>

On May 9, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the second quarter of fiscal year 2024 that ended March 31, 2024.The company currently has 14 clinical stage programs, with 10 of them being wholly owned.We expect a total of 18 clinical programs by the year end.

ARWR: Summer Webinar Series to Highlight Development Pipeline 